#JPM22, Day 1: Bristol Myers Squibb's blockbuster losses of exclusivity, Novartis' spending plans and more

After last month's pivot from an in-person event amid omicron concerns, the annual J.P. Morgan healthcare conference has finally kicked off virtually. So boot up those computers and get your meeting links ready, because it's set to be a week full of biopharma action.

Here's your Day 1 need to know, featuring Bristol Myers Squibb's plan to grow despite knockoff competition to its top drugs, Novartis' spending plans and more.